CD274 and neoplasm: Prospective cellular immunotherapy trials should integrate intratumoral and systemic microbiome signatures with tumor-intrinsic (TMB, HLA genotype, PD-L1) and circulating biomarkers (ctDNA, immune cell clonality) to build multi-modal predictive models that stratify patients by likelihood of response [129,130].